These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 27357210)

  • 1. First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?
    Fabi A; Malaguti P; Vari S; Cognetti F
    J Exp Clin Cancer Res; 2016 Jun; 35():104. PubMed ID: 27357210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.
    De Mattos-Arruda L; Cortes J
    Adv Ther; 2013 Jul; 30(7):645-58. PubMed ID: 23881722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pertuzumab in HER2-positive breast cancer.
    Sendur MA; Aksoy S; Altundag K
    Curr Med Res Opin; 2012 Oct; 28(10):1709-16. PubMed ID: 22953713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
    Nielsen DL; Kümler I; Palshof JA; Andersson M
    Breast; 2013 Feb; 22(1):1-12. PubMed ID: 23084121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.
    Farhat F; Kattan JG; Ghosn M
    Cancer Chemother Pharmacol; 2016 May; 77(5):1069-77. PubMed ID: 27059339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and future anti-HER2 therapy in breast cancer.
    Vrbic S; Pejcic I; Filipovic S; Kocic B; Vrbic M
    J BUON; 2013; 18(1):4-16. PubMed ID: 23613383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2-positive breast cancer.
    Loibl S; Gianni L
    Lancet; 2017 Jun; 389(10087):2415-2429. PubMed ID: 27939064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.
    Kawajiri H; Takashima T; Kashiwagi S; Noda S; Onoda N; Hirakawa K
    Expert Rev Anticancer Ther; 2015 Jan; 15(1):17-26. PubMed ID: 25494663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer.
    Baselga J; Swain SM
    Clin Breast Cancer; 2010 Dec; 10(6):489-91. PubMed ID: 21147694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2-targeted therapy for early-stage breast cancer: a comprehensive review.
    Brown-Glaberman U; Dayao Z; Royce M
    Oncology (Williston Park); 2014 Apr; 28(4):281-9. PubMed ID: 24839797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting HER2 in Advanced Breast Cancer.
    Zhu X; Joy AA
    Methods Mol Biol; 2017; 1652():63-77. PubMed ID: 28791634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects.
    Brandão M; Pondé NF; Poggio F; Kotecki N; Salis M; Lambertini M; de Azambuja E
    Expert Rev Anticancer Ther; 2018 Jul; 18(7):629-649. PubMed ID: 29781317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy.
    Rocca A; Andreis D; Fedeli A; Maltoni R; Sarti S; Cecconetto L; Pietri E; Schirone A; Bravaccini S; Serra P; Farolfi A; Amadori D
    Expert Opin Drug Metab Toxicol; 2015; 11(10):1647-63. PubMed ID: 26307328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2-positive metastatic breast cancer: a comprehensive review.
    Exman P; Tolaney SM
    Clin Adv Hematol Oncol; 2021 Jan; 19(1):40-50. PubMed ID: 33493147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients.
    Del Mastro L; Lambertini M; Bighin C; Levaggi A; D'Alonzo A; Giraudi S; Pronzato P
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1391-405. PubMed ID: 23072512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pertuzumab and its accelerated approval: evolving treatment paradigms and new challenges in the management of HER2-positive breast cancer.
    O'Sullivan CC; Connolly RM
    Oncology (Williston Park); 2014 Mar; 28(3):186-94, 196. PubMed ID: 24855725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2-family signalling mechanisms, clinical implications and targeting in breast cancer.
    Elster N; Collins DM; Toomey S; Crown J; Eustace AJ; Hennessy BT
    Breast Cancer Res Treat; 2015 Jan; 149(1):5-15. PubMed ID: 25542271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging drugs targeting human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer.
    Awada G; Gombos A; Aftimos P; Awada A
    Expert Opin Emerg Drugs; 2016; 21(1):91-101. PubMed ID: 26817602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pertuzumab: a new anti-HER2 drug in the management of women with breast cancer.
    Dawood S; Sirohi B
    Future Oncol; 2015; 11(6):923-31. PubMed ID: 25760974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.